SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Visit website
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS
Business
Early November Brings More Quarterly Reports
Biopharma companies set to release financial reports next week have reported positive news in recent months.
November 1, 2018
 · 
3 min read
 · 
Alex Keown
Business
Roche and AbbVie Push Towards First-Line CLL Treatment
A study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.
November 1, 2018
 · 
3 min read
 · 
Mark Terry
FDA
FDA Approves Humira Biosimilar That Won’t Be Available Until 2023
The U.S. Food and Drug Administration (FDA) gave the green light to Hyrimoz, a biosimilar to AbbVie’s blockbuster drug Humira, five years ahead of the time it can be launched in U.S. markets.
November 1, 2018
 · 
2 min read
 · 
Alex Keown
Top 12 Life Science Companies Hiring Now
Fall is in full swing, but not falling short of jobs. Check out the top companies who are looking for candidates like you right now!
October 31, 2018
 · 
1 min read
 · 
Editorial Staff
Business
Galapagos and AbbVie restructure CF collaboration
Galapagos NV announce a restructuring of their cystic fibrosis (CF) alliance; AbbVie takes over all programs in CF and continues the development of a triple combination therapy for CF.
October 30, 2018
 · 
5 min read
Deals
AbbVie Takes Over Galapagos Cystic Fibrosis Collaboration Instead of Walking Away
What is AbbVie thinking? That’s the question of many investors, analysts and industry watchers as the Chicago-based AbbVie decided to buy up researcher partner Galapagos’ cystic fibrosis portfolio instead of walking away.
October 25, 2018
 · 
3 min read
 · 
Mark Terry
Business
Ready to Roll! Ten Q3 Biotech Earnings Reports to Watch Next Week
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
October 24, 2018
 · 
5 min read
 · 
Mark Terry
Jonathan Weiss/Shutterstock
Drug Development
Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies
Eli Lilly and Company presented positive data from two Phase III clinical trials at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago yesterday.
October 23, 2018
 · 
3 min read
 · 
Mark Terry
Job Trends
BioSpace Movers and Shakers - Oct. 22
Execs at Novo Nordisk, AbbVie, and more made moves this week. Here’s a roundup of those changes.
October 19, 2018
 · 
4 min read
 · 
Alex Keown
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
Business
AbbVie and Genmab Announce Broad Oncology Collaboration
June 10, 2020
 · 
11 min read
Biotech Bay
MBC BioLabs and AbbVie Announce Winners of the 2020 AbbVie Golden Ticket
June 9, 2020
 · 
4 min read
Drug Development
AbbVie Presents Data Showing RINVOQ™ (upadacitinib) Meets Primary and Key Secondary Endpoints in Phase 3 Head-to-Head Study Versus ORENCIA (abatacept) in Rheumatoid Arthritis Patients
June 6, 2020
 · 
16 min read
Genetown
AbbVie, Harbour BioMed, Utrecht University and Erasmus Medical Center Announce Collaboration to Develop Monoclonal Antibody Therapy to Prevent and Treat COVID-19
June 5, 2020
 · 
4 min read
Drug Development
New Long-term Data from RINVOQ™ (upadacitinib, 15 mg) Phase 3 Studies in Rheumatoid Arthritis Presented at 2020 Annual European E-Congress of Rheumatology (EULAR)
June 4, 2020
 · 
21 min read
BioMidwest
AbbVie to Present at the Virtual Goldman Sachs 41st Annual Global Healthcare Conference
June 3, 2020
 · 
2 min read
BioMidwest
AbbVie Submits Regulatory Applications to FDA and EMA for RINVOQ™ (upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
June 1, 2020
 · 
16 min read
Business
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors
June 1, 2020
 · 
3 min read
FDA
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
May 29, 2020
 · 
13 min read
BioMidwest
AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio
May 27, 2020
 · 
19 min read
Load More